Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

CCCCC4 Therapeutics, Inc.

Nasdaq · CIK 0001662579
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts291

Identity from submissions API

NameC4 Therapeutics, Inc.
CIK0001662579
TickersCCCC
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN475617627
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(617) 231-0700
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
490 ARSENAL WAY
SUITE 120
WATERTOWN
MA
02472
MA
Mailing address
490 ARSENAL WAY
SUITE 120
WATERTOWN
MA
02472
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

552 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000277 005-91763 261562632 34 15772
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002050709-26-000030 005-91763 261557842 34 81502
2026-11-13 4 FORM 4 0001470831-26-001003 5402
2026-11-12 144 xsl144X01/primary_doc.xml 0001950047-26-011041 001-39567 261547388 33 5015
2026-11-05 10-Q 10-Q 0001628280-26-070575 001-39567 261524792 34 7019231 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001628280-26-070560 001-39567 261524761 34 2051378 1 1
2026-10-02 4 FORM 4 0001470831-26-000925 10099
2026-10-02 4 FORM 4 0001470831-26-000924 5139
2026-09-25 8-K 8-K 7.01,8.01,9.01 0001628280-26-063497 001-39567 261406242 34 5543089 1 1
2026-09-21 4 FORM 4 0001470831-26-000895 6751
2026-08-14 144 xsl144X01/primary_doc.xml 0001950047-26-008193 001-39567 261284297 33 7546
2026-08-14 144 xsl144X01/primary_doc.xml 0001950047-26-008190 001-39567 261284240 33 7063
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-000920 005-91763 261282949 34 15709
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000902664-26-003524 005-91763 261282669 34 12662
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002050709-26-000022 005-91763 261279001 34 81464
2026-08-13 144 xsl144X01/primary_doc.xml 0001950047-26-008065 001-39567 261273718 33 6210
2026-08-12 144 xsl144X01/primary_doc.xml 0001950047-26-008039 001-39567 261268931 33 5465
2026-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000895421-26-000231 005-91763 261268214 34 13803
2026-08-11 10-Q 10-Q 0001628280-26-055494 001-39567 261260617 34 31031808 1 1
2026-08-11 8-K 8-K 2.02,9.01 0001628280-26-055490 001-39567 261260604 34 238699 1 1
2026-07-27 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002217 005-91763 261206114 34 10837
2026-07-13 4 FORM 4 0001470831-26-000705 6714
2026-07-02 4 FORM 4 0001470831-26-000688 10096
2026-07-02 4 FORM 4 0001470831-26-000689 5136
2026-06-26 4 FORM 4 0001470831-26-000673 5529
2026-06-26 4 FORM 4 0001470831-26-000670 5562
2026-06-26 4 FORM 4 0001470831-26-000667 5575
2026-06-26 4 FORM 4 0001470831-26-000665 5568
2026-06-26 4 FORM 4 0001470831-26-000663 5595
2026-06-26 4 FORM 4 0001470831-26-000661 5533
2026-06-26 4 FORM 4 0001470831-26-000659 5554
2026-06-26 4 FORM 4 0001470831-26-000657 5519
2026-06-24 8-K 8-K 5.07,9.01 0001628280-26-045194 001-39567 261116140 34 402942 1 1
2026-06-11 8-K 8-K 7.01,8.01,9.01 0001628280-26-042365 001-39567 261081424 34 6666645 1 1
2026-06-04 4 FORM 4 0001470831-26-000504 11903
2026-05-28 144 xsl144X01/primary_doc.xml 0001193125-26-245847 001-39567 261038622 33 4397
2026-05-19 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002050709-26-000018 005-91763 26998725 34 80756
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003479 005-91763 26988031 34 12394
2026-05-15 8-K 8-K 5.02 0001628280-26-035542 001-39567 26986814 34 148084 1 1
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003216 005-91763 26982441 34 19052
2026-05-12 10-Q 10-Q 0001628280-26-033865 001-39567 26965845 34 6307083 1 1
2026-05-12 8-K 8-K 2.02,7.01,9.01 0001628280-26-033861 001-39567 26965830 34 3995449 1 1
2026-04-29 ARS ARS 0001628280-26-028109 001-39567 26910490 34 52619850
2026-04-29 DEFA14A DEFA14A 0001628280-26-028108 001-39567 26910487 34 1301766
2026-04-29 DEF 14A DEF 14A 0001628280-26-028104 001-39567 26910467 34 4032125 1 1
2026-04-22 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000814133-26-000050 005-91763 26884831 34 7388
2026-04-10 8-K 8-K 5.03,9.01 0001628280-26-024583 001-39567 26853143 34 421423 1 1
2026-04-09 8-K 8-K 1.01,7.01,9.01 0001628280-26-024336 001-39567 26849797 34 4308825 1 1
2026-04-03 4 FORM 4 0001470831-26-000346 10096
2026-04-03 4 FORM 4 0001470831-26-000345 5136
2026-03-09 144 xsl144X01/primary_doc.xml 0001950047-26-002361 001-39567 26735253 33 5473
2026-02-26 S-8 S-8 0001628280-26-012002 333-293775 26681751 33 234993 1 1
2026-02-26 10-K 10-K 0001628280-26-012000 001-39567 26681746 34 12544005 1 1
2026-02-26 8-K 8-K 2.02,9.01 0001628280-26-011971 001-39567 26681683 34 241350 1 1
2026-02-18 4 FORM 4 0001470831-26-000180 11467
2026-02-18 4 FORM 4 0001470831-26-000179 8523
2026-02-18 4 FORM 4 0001470831-26-000178 11462
2026-02-18 4 FORM 4 0001470831-26-000177 376948
2026-02-18 4 FORM 4 0001470831-26-000176 8511
2026-02-18 4 FORM 4 0001470831-26-000175 11467
2026-02-18 4 FORM 4 0001470831-26-000174 8533
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000947871-26-000188 005-91763 26644171 34 15262
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001046 005-91763 26639369 34 10521
2026-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-26-015656 005-91763 26627424 34 31618
2026-02-11 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000895421-26-000033 005-91763 26619621 34 11861
2026-01-16 4 FORM 4 0001470831-26-000045 4511
2026-01-14 8-K 8-K 7.01,9.01 0001628280-26-002010 001-39567 26531449 34 195715 1 1
2026-01-05 4 FORM 4 0001470831-26-000009 372190
2026-01-05 4 FORM 4 0001470831-26-000008 5002
2025-12-10 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-003638 333-291696 251563394 33 1765
2025-12-10 424B5 424B5 0001193125-25-314449 333-291696 251562890 33 388977
2025-12-08 CORRESP filename1.htm 0001628280-25-055804 12228
2025-11-21 S-3 S-3 0001628280-25-053575 333-291696 251507867 33 27489258 1 1
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000947871-25-001020 005-91763 251488585 34 15160
2025-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000814133-25-000117 005-91763 251479957 34 6395
2025-11-06 10-Q 10-Q 0001628280-25-049854 001-39567 251456124 34 6659448 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001628280-25-049850 001-39567 251456106 34 240318 1 1
2025-10-30 4 4 0001193125-25-258664 6406
2025-10-24 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000950130-25-000220 005-91763 251416535 34 135702
2025-10-24 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001346824-25-000025 005-91763 251416337 34 20075
2025-10-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004471 005-91763 251404988 34 21303
2025-10-16 8-K 8-K 1.01,9.01 0001193125-25-241591 001-39567 251398485 34 861664 1 1
2025-10-16 424B5 424B5 0001193125-25-241586 333-282933 251398482 33 560613
2025-10-16 FWP FWP 0001193125-25-240800 333-282933 251396363 34 153176
2025-10-16 8-K 8-K 8.01 0001628280-25-045157 001-39567 251396350 34 5254707 1 1
2025-10-03 4 FORM 4 0001470831-25-000250 9743
2025-10-03 4 FORM 4 0001470831-25-000249 5003
2025-10-01 8-K 8-K 7.01,8.01,9.01 0001628280-25-043290 001-39567 251362549 34 178493 1 1
2025-09-22 8-K 8-K 7.01,8.01,9.01 0001628280-25-042245 001-39567 251328367 34 6380449 1 1
2025-09-19 4 FORM 4 0001470831-25-000223 6614
2025-08-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000895421-25-000489 005-91763 251192833 34 7938
2025-08-07 10-Q 10-Q 0001628280-25-038587 001-39567 251191564 34 6350858 1 1
2025-08-07 8-K 8-K 2.02,7.01,8.01,9.01 0001628280-25-038576 001-39567 251191526 34 3863925 1 1
2025-07-16 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-002489 005-91763 251128457 34 10800
2025-07-15 4/A FORM 4/A 0001662579-25-000057 6750
2025-07-14 4 FORM 4 0001662579-25-000055 4817
2025-07-02 4 FORM 4 0001662579-25-000053 9740
2025-07-02 4 FORM 4 0001662579-25-000052 5000
2025-06-20 4 FORM 4 0001662579-25-000049 5439
2025-06-20 4 FORM 4 0001662579-25-000048 5408
2025-06-20 4 FORM 4 0001662579-25-000047 5418
2025-06-20 4 FORM 4 0001662579-25-000046 5432
2025-06-20 4 FORM 4 0001662579-25-000045 5397
2025-06-20 4 FORM 4 0001662579-25-000044 5383
2025-06-20 4 FORM 4 0001662579-25-000043 5459
2025-06-20 4 FORM 4 0001662579-25-000042 5426
2025-06-18 8-K 8-K 5.03,5.07,9.01 0001628280-25-032155 001-39567 251057568 34 466405 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000947871-25-000543 005-91763 25956616 34 14940
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-013188 005-91763 25954917 34 17051
2025-05-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000814133-25-000035 005-91763 25920509 34 6542
2025-05-07 10-Q 10-Q 0001628280-25-022866 001-39567 25919252 34 6073473 1 1
2025-05-07 8-K 8-K 2.02,7.01,8.01,9.01 0001628280-25-022864 001-39567 25919244 34 4276315 1 1
2025-04-29 ARS ARS 0001628280-25-020468 001-39567 25882612 34 53299356
2025-04-29 DEFA14A DEFA14A 0001628280-25-020467 001-39567 25882601 34 2258170 1 1
2025-04-29 DEF 14A DEF 14A 0001628280-25-020466 001-39567 25882596 34 2447327 1 1
2025-04-16 PRE 14A PRE 14A 0001628280-25-017927 001-39567 25841241 34 2414807 1 1
2025-04-14 8-K 8-K 5.02 0001628280-25-017612 001-39567 25834266 34 150960 1 1
2025-04-03 4 FORM 4 0001662579-25-000025 5001
2025-04-03 4 FORM 4 0001662579-25-000024 9741
2025-02-27 S-8 S-8 0001628280-25-008434 333-285304 25672994 33 138830
2025-02-27 10-K 10-K 0001628280-25-008433 001-39567 25672983 34 31568329 1 1
2025-02-27 8-K 8-K 2.02,9.01 0001628280-25-008429 001-39567 25672960 34 254988 1 1
2025-02-18 4 FORM 4 0001662579-25-000021 10204
2025-02-18 4 FORM 4 0001662579-25-000020 10205
2025-02-18 4 FORM 4 0001662579-25-000019 13160
2025-02-18 4 FORM 4 0001662579-25-000018 4855
2025-02-18 4 FORM 4 0001662579-25-000017 10205
2025-02-18 4 FORM 4 0001662579-25-000016 10212
2025-02-18 4 FORM 4 0001662579-25-000015 7187
2025-02-18 4 FORM 4 0001662579-25-000014 8780
2025-02-03 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000895421-25-000188 005-91763 25581835 34 7832
2025-01-14 8-K 8-K 2.02,7.01 0001628280-25-001433 001-39567 25527748 34 5922538 1 1
2025-01-03 4 FORM 4 0001662579-25-000004 5009
2025-01-03 4 FORM 4 0001662579-25-000003 9749
2024-12-09 8-K 8-K 8.01,9.01 0001628280-24-050349 001-39567 241534072 34 10827866 1 1
2024-11-21 4 FORM 4 0001662579-24-000108 5437
2024-11-21 3 FORM 3 0001662579-24-000107 7418
2024-11-20 8-K 8-K 5.02,7.01,9.01 0001628280-24-048593 001-39567 241478271 34 186520 1 1
2024-11-18 144 xsl144X01/primary_doc.xml 0001972362-24-001664 001-39567 241472052 33 5560
2024-11-15 424B3 424B3 0001628280-24-048091 333-282934 241467850 33 187777
2024-11-15 424B5 424B5 0001628280-24-048088 333-282933 241467819 33 158439
2024-11-14 SC 13G/A C4 THERAPEUTICS, INC. 0000902664-24-006655 005-91763 241465310 34 76258
2024-11-14 SC 13G SCHEDULE 13G 0000947871-24-000915 005-91763 241465072 34 68688
2024-11-14 SC 13G/A formsc13ga.htm 0001493152-24-045843 005-91763 241461869 34 90877
2024-11-14 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0001213900-24-098320 005-91763 241461018 34 136320
2024-11-14 SC 13G/A cccc13gasep24.txt 0000080255-24-001455 005-91763 34 6688
2024-11-14 SC 13G/A C4 THERAPEUTICS, INC. 0000902664-24-006516 005-91763 241457607 34 66671
2024-11-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-11-13 16:05:00 9999999995-24-003480 333-282934 241456695 33 1772
2024-11-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-11-13 16:05:00 9999999995-24-003479 333-282933 241456694 33 1772
2024-11-13 SUPPL SUPPL 0001628280-24-047659 333-282933 241455374 NE 158467
2024-11-13 SUPPL SUPPL 0001628280-24-047658 333-282934 241455368 NE 195133
2024-11-12 4 FORM 4 0001662579-24-000104 8597
2024-11-12 4 FORM 4 0001662579-24-000103 8596
2024-11-12 4 FORM 4 0001662579-24-000102 8592
2024-11-12 4 FORM 4 0001662579-24-000101 8576
2024-11-12 4 FORM 4 0001662579-24-000100 8593
2024-11-08 CORRESP filename1.htm 0001628280-24-046658 27854
2024-11-08 CORRESP filename1.htm 0001628280-24-046657 27856
2024-11-08 SC 13G us12529r1077_110824.txt 0002012383-24-003684 005-91763 241439838 34 13731
2024-11-07 UPLOAD filename1.pdf 0000000000-24-012425 333-282934 40153
2024-11-07 UPLOAD filename1.pdf 0000000000-24-012423 333-282933 40155
2024-10-31 S-3 S-3 0001628280-24-044613 333-282934 241416287 33 359411
2024-10-31 S-3 S-3 0001628280-24-044612 333-282933 241416286 33 43124847
2024-10-31 10-Q 10-Q 0001628280-24-044411 001-39567 241412411 34 6389876 1 1
2024-10-31 8-K 8-K 2.02,9.01 0001628280-24-044409 001-39567 241412401 34 260009 1 1
2024-10-29 4 FORM 4 0001662579-24-000094 7330
2024-10-29 3 FORM 3 0001662579-24-000092 7487
2024-10-22 SC 13G us12529r1077_102224.txt 0002012383-24-001634 005-91763 241387359 34 13719
2024-10-18 144 xsl144X01/primary_doc.xml 0001972362-24-001412 001-39567 241381208 33 4878
2024-10-16 8-K/A 8-K/A 5.02,7.01,9.01 0001628280-24-042879 001-39567 241372901 34 3113559 1 1
2024-10-15 8-K 8-K 5.02,7.01,9.01 0001628280-24-042833 001-39567 241371958 34 3111505 1 1
2024-10-11 144 xsl144X01/primary_doc.xml 0001972362-24-001402 001-39567 241368572 33 4270
2024-10-11 8-K 8-K 5.02,9.01 0001628280-24-042728 001-39567 241367662 34 417221 1 1
2024-10-02 4 FORM 4 0001662579-24-000090 5014
2024-10-02 4 FORM 4 0001662579-24-000089 9750
2024-09-20 4 FORM 4 0001662579-24-000086 4836
2024-09-17 4 FORM 4 0001662579-24-000084 8590
2024-09-17 4 FORM 4 0001662579-24-000083 8596
2024-09-17 4 FORM 4 0001662579-24-000082 8595
2024-09-17 4 FORM 4 0001662579-24-000081 8602
2024-09-17 4 FORM 4 0001662579-24-000080 8591
2024-09-17 4 FORM 4 0001662579-24-000079 8575
2024-09-03 4 FORM 4 0001662579-24-000072 5427
2024-09-03 3 FORM 3 0001662579-24-000070 7407
2024-09-03 8-K 8-K 5.02,7.01,9.01 0001628280-24-039023 001-39567 241271885 34 193001 1 1
2024-08-01 10-Q 10-Q 0001628280-24-033882 001-39567 241164275 34 5916841 1 1
2024-08-01 8-K 8-K 2.02 0001628280-24-033874 001-39567 241164245 34 248745 1 1
2024-07-11 4 FORM 4 0001662579-24-000066 4821
2024-07-10 SC 13G/A C4_Therapeutics_Inc.txt 0000093751-24-000658 005-91763 241108656 34 8429
2024-07-02 4 FORM 4 0001662579-24-000064 5007
2024-07-02 4 FORM 4 0001662579-24-000063 9747
2024-06-21 4 FORM 4 0001662579-24-000060 5415
2024-06-21 4 FORM 4 0001662579-24-000059 5404
2024-06-21 4 FORM 4 0001662579-24-000058 5446
2024-06-21 4 FORM 4 0001662579-24-000057 5280
2024-06-21 4 FORM 4 0001662579-24-000056 5425
2024-06-21 4 FORM 4 0001662579-24-000055 5439
2024-06-21 8-K 8-K 5.07 0001628280-24-029301 001-39567 241060199 34 167453 1 1
2024-06-21 4 FORM 4 0001662579-24-000054 5390
2024-06-11 4 FORM 4 0001662579-24-000046 5465
2024-06-11 3 FORM 3 0001662579-24-000044 7443
2024-06-10 8-K 8-K 5.02,7.01,9.01 0001628280-24-027399 001-39567 241031479 34 191224 1 1
2024-05-08 10-Q 10-Q 0001628280-24-021368 001-39567 24924224 34 24256688 1 1
2024-05-08 8-K 8-K 2.02,9.01 0001628280-24-021367 001-39567 24924215 34 236760 1 1
2024-04-30 ARS ARS 0001628280-24-019204 001-39567 24894201 34 53011987
2024-04-29 DEFA14A DEFA14A 0001628280-24-018787 001-39567 24886677 34 463577 1 1
2024-04-29 DEF 14A DEF 14A 0001628280-24-018785 001-39567 24886672 34 2568449 1 1
2024-04-10 4 FORM 4 0001662579-24-000040 7393
2024-04-10 SC 13G C4_Therapeutics_Inc.txt 0000093751-24-000578 005-91763 24834425 34 10261
2024-04-02 4 FORM 4 0001662579-24-000038 9747
2024-04-02 4 FORM 4 0001662579-24-000037 7277
2024-04-02 4 FORM 4 0001662579-24-000036 5007
2024-03-08 4 FORM 4 0001662579-24-000032 7889
2024-03-08 4 FORM 4 0001662579-24-000030 12248
2024-03-08 4 FORM 4 0001662579-24-000028 12270
2024-03-08 4 FORM 4 0001662579-24-000026 7918
2024-03-08 4 FORM 4 0001662579-24-000024 12218
2024-03-08 8-K 8-K 5.02 0001628280-24-009967 001-39567 24734425 34 160498 1 1
2024-03-08 SC 13G/A cccc324.txt 0000814133-24-000064 005-91763 24733403 34 4163
2024-03-04 8-K 8-K 1.01,7.01,9.01 0001628280-24-008339 001-39567 24712822 34 194393 1 1
2024-02-22 S-8 S-8 0001628280-24-006168 333-277245 24662481 33 135225
2024-02-22 10-K 10-K 0001628280-24-006144 001-39567 24662289 34 39472722 1 1
2024-02-22 8-K 8-K 2.02,9.01 0001628280-24-006142 001-39567 24662281 34 246205 1 1
2024-02-15 4 FORM 4 0001662579-24-000022 4847
2024-02-15 4 FORM 4 0001662579-24-000020 7174
2024-02-15 4 FORM 4 0001662579-24-000019 7149
2024-02-15 4 FORM 4 0001662579-24-000018 8787
2024-02-15 4 FORM 4 0001662579-24-000017 8803
2024-02-15 4 FORM 4 0001662579-24-000016 8814
2024-02-15 4 FORM 4 0001662579-24-000015 8808
2024-02-15 4 FORM 4 0001662579-24-000014 8807
2024-02-14 SC 13G/A cccc13gadec23.txt 0000080255-24-000751 005-91763 34 6505
2024-02-14 SC 13G/A C4 THERAPEUTICS, INC. 0000902664-24-001611 005-91763 24633037 34 64723
2024-02-14 SC 13G/A C4 THERAPEUTICS, INC. 0000902664-24-001562 005-91763 24632321 34 61958
2024-02-09 SC 13G/A cccc224.txt 0000814133-24-000028 005-91763 24613683 34 4165
2024-02-05 SC 13G SCHEDULE 13G 0001213900-24-009888 005-91763 24594423 34 110754
2024-02-02 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0001213900-24-009358 005-91763 24589019 34 99176
2024-01-12 SC 13G SC 13G 0001193125-24-007490 005-91763 24532040 34 61436
2024-01-11 8-K 8-K 7.01,9.01 0001628280-24-001085 001-39567 24527952 34 4726312 1 1
2024-01-09 8-K 8-K 2.05,7.01,9.01 0001628280-24-000947 001-39567 24523307 34 218326 1 1
2024-01-04 SC 13G C4 THERAPEUTICS, INC. 0000902664-24-000047 005-91763 24512053 34 85161
2024-01-03 4 FORM 4 0001662579-24-000006 7279
2024-01-03 4 FORM 4 0001662579-24-000005 9749
2024-01-03 4 FORM 4 0001662579-24-000004 5009
2023-12-26 SC 13G SC 13G 0001104659-23-129222 005-91763 231513661 34 82985
2023-12-22 SC 13G formsc13g.htm 0001493152-23-045910 005-91763 231509776 34 97989
2023-12-12 8-K 8-K 7.01,8.01,9.01 0001628280-23-041317 001-39567 231481562 34 5495404 1 1
2023-12-12 8-K 8-K 1.01,7.01,9.01 0001628280-23-041271 001-39567 231479945 34 196167 1 1
2023-11-20 4 FORM 4 0001662579-23-000114 5338
2023-11-20 3 FORM 3 0001662579-23-000112 7312
2023-11-20 8-K 8-K 5.02,7.01,9.01 0001628280-23-039562 001-39567 231420697 34 191445 1 1
2023-11-13 SC 13G C4 THERAPEUTICS, INC. 0000902664-23-005480 005-91763 231399764 34 67844
2023-11-01 10-Q 10-Q 0001628280-23-035793 001-39567 231366576 34 7506694 1 1
2023-11-01 8-K 8-K 2.02,9.01 0001628280-23-035790 001-39567 231366559 34 256673 1 1
2023-10-03 4 FORM 4 0001662579-23-000109 9668
2023-10-03 4 FORM 4 0001662579-23-000108 7198
2023-10-03 4 FORM 4 0001662579-23-000107 4928
2023-09-19 4 FORM 4 0001662579-23-000102 5270
2023-09-19 4 FORM 4 0001662579-23-000101 5275
2023-09-19 4 FORM 4 0001662579-23-000100 5284
2023-09-19 4 FORM 4 0001662579-23-000099 5280
2023-09-19 4 FORM 4 0001662579-23-000098 5259
2023-09-19 4 FORM 4 0001662579-23-000097 7213
2023-09-19 3 FORM 3 0001662579-23-000096 8672
2023-09-19 3 FORM 3 0001662579-23-000095 13676
2023-09-05 8-K 8-K 5.02,9.01 0001628280-23-031375 001-39567 231235664 34 6400968 1 1
2023-08-31 4 FORM 4 0001662579-23-000086 8508
2023-08-31 4 FORM 4 0001662579-23-000085 8493
2023-08-31 4 FORM 4 0001662579-23-000084 8513
2023-08-31 4 FORM 4 0001662579-23-000083 8509
2023-08-31 4 FORM 4 0001662579-23-000082 8520
2023-08-31 4 FORM 4 0001662579-23-000081 8514
2023-08-08 10-Q 10-Q 0001628280-23-027941 001-39567 231149306 34 5855395 1 1
2023-08-08 8-K 8-K 2.02,9.01 0001628280-23-027935 001-39567 231149278 34 261729 1 1
2023-07-25 SC 13G CCCC_SC13G.htm 0001273087-23-000125 005-91763 231109065 34 82051
2023-07-12 4 FORM 4 0001662579-23-000074 7207
2023-07-12 3 FORM 3 0001662579-23-000073 7370
2023-07-07 SC 13G/A us12529r1077_070723.txt 0001306550-23-009607 005-91763 231077274 34 12486
2023-07-05 4 FORM 4 0001662579-23-000068 9665
2023-07-05 4 FORM 4 0001662579-23-000067 7196
2023-07-05 4 FORM 4 0001662579-23-000066 4926
2023-06-20 8-K 8-K 5.02,5.07,9.01 0001628280-23-022597 001-39567 231023363 34 237626 1 1
2023-06-16 4 FORM 4 0001662579-23-000062 5357
2023-06-16 4 FORM 4 0001662579-23-000061 5322
2023-06-16 4 FORM 4 0001662579-23-000060 5198
2023-06-16 4 FORM 4 0001662579-23-000059 5358
2023-06-16 4 FORM 4 0001662579-23-000058 5308
2023-06-16 4 FORM 4 0001662579-23-000057 5364
2023-06-16 4 FORM 4 0001662579-23-000055 5343
2023-06-12 SC 13G/A arrowmark-cccc053123a2.htm 0001172661-23-002371 005-91763 231008209 34 54172
2023-05-30 8-K 8-K 1.01,3.02,9.01 0001628280-23-020025 001-39567 23971395 34 1367811 1 1
2023-05-04 10-Q 10-Q 0001628280-23-015459 001-39567 23886567 34 6281089 1 1
2023-05-04 8-K 8-K 2.02,9.01 0001628280-23-015454 001-39567 23886508 34 253217 1 1
2023-05-03 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001628280-23-004824,2023-05-03 9999999995-23-001249 333-260972 23886160 33 1735
2023-04-28 ARS ARS 0001628280-23-013742 001-39567 23860093 34 41391984
2023-04-28 DEFA14A DEFA14A 0001628280-23-013741 001-39567 23860085 34 545373 1 1
2023-04-28 DEF 14A DEF 14A 0001628280-23-013738 001-39567 23860077 34 2295706 1 1
2023-04-18 PRE 14A PRE 14A 0001628280-23-011846 001-39567 23825516 34 2308820 1 1
2023-04-14 SC 13G SC 13G 0001193125-23-102252 005-91763 23821966 34 107265
2023-04-04 4 FORM 4 0001662579-23-000046 7277
2023-04-04 4 FORM 4 0001662579-23-000045 9747
2023-04-04 4 FORM 4 0001662579-23-000044 5007
2023-02-23 8-K/A 8-K/A 2.02,9.01 0001628280-23-004835 001-39567 23659897 34 248460 1 1
2023-02-23 S-8 S-8 0001628280-23-004830 333-269944 23659858 33 97065
2023-02-23 POS AM POS AM 0001628280-23-004824 333-260972 23659739 33 476845
2023-02-23 10-K 10-K 0001628280-23-004711 001-39567 23656280 34 16051745 1 1
2023-02-23 POSASR POSASR 0001628280-23-004707 333-260972 23656065 33 578492
2023-02-23 8-K 8-K 2.02,9.01 0001662579-23-000040 001-39567 23655971 34 249109 1 1
2023-02-15 4 FORM 4 0001662579-23-000039 7116
2023-02-15 4 FORM 4 0001662579-23-000038 7087
2023-02-15 4 FORM 4 0001662579-23-000037 7108
2023-02-15 4 FORM 4 0001662579-23-000036 7103
2023-02-15 4 FORM 4 0001662579-23-000035 7110
2023-02-15 4 FORM 4 0001662579-23-000034 7102
2023-02-14 SC 13G arrowmark-cccc123122a1.htm 0001172661-23-001446 005-91763 23632039 34 53976
2023-02-14 SC 13G/A cccc13gadec22.txt 0000080255-23-002715 005-91763 34 6865
2023-02-14 SC 13G/A C4 THERAPEUTICS, INC. 0000902664-23-001723 005-91763 23623855 34 62523
2023-02-10 4 FORM 4 0001662579-23-000027 4477
2023-02-08 SC 13G/A cccc223.txt 0000814133-23-000031 005-91763 23598899 34 3987
2023-02-02 8-K 8-K 5.02,7.01 0001628280-23-002041 001-39567 23580809 34 232176 1 1
2023-02-01 4 FORM 4 0001662579-23-000024 8522
2023-02-01 4 FORM 4 0001662579-23-000023 8522
2023-02-01 4 FORM 4 0001662579-23-000022 8523
2023-02-01 4 FORM 4 0001662579-23-000021 8519
2023-02-01 4 FORM 4 0001662579-23-000020 8518
2023-02-01 4 FORM 4 0001662579-23-000019 8502
2023-02-01 4 FORM 4 0001662579-23-000018 8529
2023-01-31 SC 13G/A us12529r1077_013123.txt 0001306550-23-005138 005-91763 23571789 34 13309
2023-01-09 8-K 8-K 7.01,9.01 0001628280-23-000725 001-39567 23516621 34 9802927 1 1
2023-01-06 4 FORM 4 0001662579-23-000008 14935
2023-01-04 4 FORM 4 0001662579-23-000006 9717
2023-01-04 4 FORM 4 0001662579-23-000005 4977
2023-01-04 4 FORM 4 0001662579-23-000004 7247
2022-11-03 10-Q 10-Q 0001628280-22-027985 001-39567 221356293 34 7451839 1 1
2022-11-03 8-K 8-K 2.02,9.01 0001628280-22-027966 001-39567 221356210 34 412130 1 1
2022-10-04 4 FORM 4 0001662579-22-000006 4976
2022-10-04 4 FORM 4 0001662579-22-000005 7248
2022-10-04 4 FORM 4 0001662579-22-000004 16850
2022-09-22 8-K/A 8-K/A 5.07 0001628280-22-025322 001-39567 221257856 34 174570 1 1
2022-08-04 10-Q 10-Q 0001628280-22-020886 001-39567 221134875 34 7321450 1 1
2022-08-04 8-K 8-K 2.02,9.01 0001628280-22-020884 001-39567 221134843 34 412015 1 1
2022-08-02 4 FORM 4 SUBMISSION 0001209191-22-043870 5317
2022-08-02 4 FORM 4 SUBMISSION 0001209191-22-043869 5331
2022-08-02 3 FORM 3 SUBMISSION 0001209191-22-043864 7201
2022-08-02 3 FORM 3 SUBMISSION 0001209191-22-043861 7215
2022-08-02 8-K 8-K 5.02,7.01,9.01 0001628280-22-020108 001-39567 221126972 34 467928 1 1
2022-07-18 4 FORM 4 SUBMISSION 0001209191-22-042457 15496
2022-07-05 4 FORM 4 SUBMISSION 0001209191-22-040603 7278
2022-07-05 4 FORM 4 SUBMISSION 0001209191-22-040597 9745
2022-06-24 8-K 8-K 5.07 0001564590-22-024179 001-39567 221039942 34 198489 1 1
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038865 5354
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038864 5355
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038863 5298
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038862 5340
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038861 5195
2022-06-17 DEFA14A DEFA14A 0001564590-22-023556 001-39567 221023815 34 28880
2022-06-17 8-K 8-K 5.02 0001564590-22-023555 001-39567 221023780 34 163186 1 1
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036718 5071
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036716 5083
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036715 5097
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036714 5097
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036713 5087
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036712 5090
2022-06-14 4/A FORM 4/A SUBMISSION 0001209191-22-036711 5092
2022-06-10 SC 13G arrowmark-cccc060222.htm 0001172661-22-001528 005-91763 221007721 34 53953
2022-06-06 SC 13G/A cccc622.txt 0000814133-22-000100 005-91763 22997466 34 3984
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032515 7154
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032514 7173
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032512 7170
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032511 7180
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032509 7180
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032510 7175
2022-05-27 4 FORM 4 SUBMISSION 0001209191-22-032508 7170
2022-05-16 8-K 8-K 8.01,9.01 0001564590-22-020438 001-39567 22930461 34 202902 1 1
2022-05-12 DEFA14A DEFA14A 0001193125-22-148612 001-39567 22917655 34 10800
2022-05-05 10-Q 10-Q 0001564590-22-018046 001-39567 22894196 34 9226386 1 1
2022-05-05 8-K 8-K 2.02,9.01 0001564590-22-018044 001-39567 22894175 34 1890103 1 1
2022-04-29 DEFA14A DEFA14A 0001193125-22-130943 001-39567 22870756 34 406511
2022-04-29 DEF 14A DEF 14A 0001193125-22-130938 001-39567 22870738 34 1559043
2022-04-12 4 FORM 4 SUBMISSION 0001209191-22-024228 10820
2022-04-12 4 FORM 4 SUBMISSION 0001209191-22-024130 4543
2022-04-08 8-K 8-K 8.01,9.01 0001564590-22-013950 001-39567 22816334 34 7977508 1 1
2022-04-05 4 FORM 4 SUBMISSION 0001209191-22-023021 7277
2022-04-05 4 FORM 4 SUBMISSION 0001209191-22-023018 5872
2022-04-05 4 FORM 4 SUBMISSION 0001209191-22-023016 9745
2022-03-17 4 FORM 4 SUBMISSION 0001209191-22-019573 5368
2022-03-17 3 FORM 3 SUBMISSION 0001209191-22-019572 7262
2022-03-17 3 FORM 3 SUBMISSION 0001209191-22-019571 11188
2022-03-17 3 FORM 3 SUBMISSION 0001209191-22-019569 9977
2022-03-16 8-K 8-K 5.02,7.01,9.01 0001564590-22-010644 001-39567 22745048 34 208589 1 1
2022-02-24 S-8 S-8 0001564590-22-006505 333-262949 22666581 33 165295
2022-02-24 10-K 10-K 0001564590-22-006499 001-39567 22666557 34 23997901 1 1
2022-02-24 8-K 8-K 2.02,9.01 0001564590-22-006496 001-39567 22666525 34 297554 1 1
2022-02-23 4 FORM 4 SUBMISSION 0001209191-22-012216 5605
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010206 8018
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010208 8017
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010207 7986
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010204 8010
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-042235 005-91763 22634956 34 67945
2022-02-14 SC 13G/A schedule13g.htm 0000929638-22-000485 005-91763 22630252 34 109255

Latest XBRL company facts

One latest value per concept from companyfacts (291 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 131.32M 2026-10-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
dei EntityPublicFloat Entity Public Float USD 100.05M 2025-06-30 2025 FY 10-K 2026-02-26 0001628280-26-012000
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 846,679 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001628280-26-028104
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.56M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001628280-26-028104
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 1.32M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001628280-26-028104
ecd PeoTotalCompAmt PeoTotalCompAmt USD 2.94M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001628280-26-028104
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 32.37 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001628280-26-028104
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 963,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 1.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 6.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 14.14M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 870,000 2023-06-30 2023 Q1 10-Q 2023-08-08 0001628280-23-027941
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 11.76M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.06M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.04B 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AdjustmentsToAdditionalPaidInCapitalOther Adjustments to Additional Paid in Capital, Other USD 26,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.98M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 8.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 117.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap Assets Assets USD 331.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AssetsCurrent Assets, Current USD 214.50M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 296.83M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.06M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 379.30M 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 375.65M 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 316.46M 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 32.42M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 63.43M 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 274.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 35.87M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD -26.57M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -42.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 8.86 2020-10-06 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 131.31M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 131.31M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap CommonStockValue Common Stock, Value, Issued USD 13,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -71.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ContractWithCustomerLiability Contract with Customer, Liability USD 33.28M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 19.52M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 13.77M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 10.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Contract with Customer, Performance Obligation Satisfied in Previous Period USD 1.34M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 256.52M 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 13.42M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 121,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 121,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 11.00M 2023-06-30 2023 Q1 10-Q 2023-08-08 0001628280-23-027941
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD 1.02M 2022-12-31 2023 FY 10-K 2024-02-22 0001628280-24-006144
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss USD 243.32M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent Debt Securities, Available-for-sale, Amortized Cost, Noncurrent USD 321.87M 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 0 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions security 0 2021-12-31 2022 FY 10-K 2023-02-23 0001628280-23-004711
us-gaap DebtSecuritiesAvailableForSaleExcludingAccruedInterest DebtSecuritiesAvailableForSaleExcludingAccruedInterest USD 242.26M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent USD 172.97M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent USD 69.29M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 111.93M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 59,000 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions security 68 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 12.87M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredRevenue Deferred Revenue USD 50.29M 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 31.27M 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 19.02M 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 6.16M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 216.50M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 100.15M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 359.60M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration USD 359.60M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 474.90M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 22,000 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsForeign Deferred Tax Assets, Tax Credit Carryforwards, Foreign USD 0 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 27.98M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 13.68M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxAssetsUnrealizedLossesOnTradingSecurities Deferred Tax Assets, Unrealized Losses on Trading Securities USD 0 2023-12-31 2023 FY 10-K 2024-02-22 0001628280-24-006144
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 203.64M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 1.11M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities Deferred Tax Liabilities, Unrealized Gains on Trading Securities USD 3,000 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 1.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay pure 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.03 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent pure 0.9 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap Depreciation Depreciation USD 1.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 1.96M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 1.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.54 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.65 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.54 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.22 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.018 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure -0.01 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.028 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap EffectiveIncomeTaxRateReconciliationTaxSettlements Effective Income Tax Rate Reconciliation, Tax Settlement, Percent pure -0.01 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 72.80M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 5.68M 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap FairValueLiabilitiesLevel1ToLevel2TransfersAmount Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap FairValueLiabilitiesLevel2ToLevel1TransfersAmount Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap FinancialLiabilitiesFairValueDisclosure Financial Liabilities Fair Value Disclosure USD 5.46M 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD -16,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 26.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -104.87M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 131,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority USD 600,000 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxPaidForeignAfterRefundReceived IncomeTaxPaidForeignAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD 131,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 23.09M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -22.02M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 52,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 1.91M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 4,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 95,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 3.01M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 105,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -996,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 828,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 4.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -4.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap InterestAndOtherIncome Interest and Other Income USD 8.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap InterestExpenseBorrowings Interest Expense, Borrowings USD 1.00M 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap InvestmentsFairValueDisclosure Investments, Fair Value Disclosure USD 135.98M 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap LeaseCost Lease, Cost USD 10.76M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 71.13M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 15.55M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 9.37M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 12.79M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 12.41M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 11.36M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 9.65M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 2.09M 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 11.14M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap Liabilities Liabilities USD 103.63M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 331.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap LiabilitiesCurrent Liabilities, Current USD 41.46M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap LongTermDebt Long-term Debt USD 11.48M 2022-12-31 2023 FY 10-K 2024-02-22 0001628280-24-006144
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 0 2023-12-31 2023 FY 10-K 2024-02-22 0001628280-24-006144
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 9.50M 2023-06-30 2023 Q1 10-Q 2023-08-08 0001628280-23-027941
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 9.50M 2020-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 9.50M 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 9.50M 2022-12-31 2022 FY 10-K 2023-02-23 0001628280-23-004711
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 1.50M 2023-06-30 2023 Q1 10-Q 2023-08-08 0001628280-23-027941
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2023-12-31 2023 FY 10-K 2024-02-22 0001628280-24-006144
us-gaap MarketableSecurities Marketable Securities USD 365.50M 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 264.10M 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 52.36M 2022-09-30 2022 Q3 10-Q 2022-11-03 0001628280-22-027985
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -619,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 34.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -19.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -57.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -70.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -83.89M 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 8.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingExpenses Operating Expenses USD 100.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -78.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingLeaseCost Operating Lease, Cost USD 9.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 10.60M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 59.98M 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 6.84M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 48.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingLeasePayments Operating Lease, Payments USD 7.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 36.17M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 4.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.053 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 4.57M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -1.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -3,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 989,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 44,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap OtherOperatingActivitiesCashFlowStatement Other Operating Activities, Cash Flow Statement USD 68,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 239,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PaymentsForRepurchaseOfInitialPublicOffering Payments for Repurchase of Initial Public Offering USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-23 0001628280-23-004711
us-gaap PaymentsForUnderwritingExpense Payments for Underwriting Expense USD 14.70M 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 500,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 8.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 180.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 101,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 135.93M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 8.47M 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 7.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 195.07M 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 33.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 145.53M 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 11.97M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap ProceedsFromPaymentsForOtherFinancingActivities Proceeds from (Payments for) Other Financing Activities USD 229,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 161.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Proceeds from Sale, Maturity and Collection of Short-term Investments USD 14.90M 2019-01-01 2019-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 63,000 2019-01-01 2019-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 1.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -70.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 15.59M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 3.83M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ReceivablesNetCurrent Receivables, Net, Current USD 1.41M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap RepaymentsOfRelatedPartyDebt Repayments of Related Party Debt USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-27 0001628280-25-008433
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 73.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 3.44M 2026-03-31 2026 Q1 10-Q 2026-05-12 0001628280-26-033865
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 3.44M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap RestructuringAndRelatedCostCostIncurredToDate1 Restructuring and Related Cost, Cost Incurred to Date USD 2.40M 2025-09-30 2025 Q3 10-Q 2025-11-06 0001628280-25-049854
us-gaap RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated Restructuring and Related Cost, Expected Number of Positions Eliminated position 45 2024-01-01 2024-03-31 2023 Q1 10-Q 2024-05-08 0001628280-24-021368
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.3 2024-01-09 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap RestructuringCharges Restructuring Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap RestructuringCosts Restructuring Costs USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-06 0001628280-25-049854
us-gaap RestructuringReserveCurrent Restructuring Reserve, Current USD 800,000 2024-03-31 2023 Q1 10-Q 2024-05-08 0001628280-24-021368
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -809.30M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer USD 7.65M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 21.26M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-22 0001628280-24-006144
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 8.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 1.12M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 15.48 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 395,676 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 730,270 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 2.99 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 5.88M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 21.29 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 5.88M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 21.29 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 4.14 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 13.55 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 3.8 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap SharePrice Share Price USD/shares 26.96 2020-10-06 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap ShortTermInvestments Short-term Investments USD 135.98M 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 228.17M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.119 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 380,688 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056223
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 256.52M 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 173,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 33.55M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD -39,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 225,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 6,634 2024-01-01 2024-09-30 2023 Q1 10-Q 2024-10-31 0001628280-24-044411
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD -78,000 2020-04-01 2020-06-30 2021 Q2 10-Q 2021-08-11 0001564590-21-043442
us-gaap SubleaseIncome Sublease Income USD 1.64M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncreaseDecreaseInEffectiveTaxRate Tax Cuts and Jobs Act, Measurement Period Adjustment, Increase (Decrease) in Effective Tax Rate pure 0.8 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0001564590-22-006499
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 111.00M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 111.00M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 146.76M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 113.15M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 113.15M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012531
us-gaap UnrealizedGainLossOnInvestments Unrealized Gain (Loss) on Investments USD 53,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053604
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 30.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap VariableLeaseCost Variable Lease, Cost USD 2.65M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 130.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 48.73M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0001564590-22-018046
us-gaap WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation shares 76.92M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001628280-26-012000
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 130.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001628280-26-070575

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →